Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Grants Orphan Drug Designation to Soquelitinib in T-Cell Lymphoma

February 9th 2024

Soquelitinib has been granted an orphan drug designation by the FDA for potential use in T-cell lymphoma.

Transplant in the Elderly Population

February 9th 2024

This session will focus on considerations and outcomes of allo-HSCT specifically among patients over 55 years of age. The panel will discuss how transplant protocols and supportive care measures can be optimized for this population who are at higher risk of comorbidities, toxicity and poor functional status.

Emerging Cellular Therapies in Hematologic Malignancies

February 9th 2024

An overview of promising novel cellular therapies showing efficacy against hematologic cancers in early-phase clinical trials.

Combination Therapies for MF Management

February 9th 2024

Panel experts comment on the role of combination therapies in MF and debate if these therapies will be the new standard of care.

Future of PV: Unmet Needs

February 9th 2024

Faculty offer insights into the future of PV management as well as unmet needs.

European Commission Grants Orphan Drug Designation to NXC-201 for AL Amyloidosis

February 8th 2024

NXC-201 has received orphan drug designation from the European Commission for use in patients with amyloid light-chain amyloidosis.

Gilead Discontinues Phase 3 ENHANCE-3 Trial of Magrolimab Plus Venetoclax/Azacitidine in AML

February 8th 2024

The phase 3 ENHANCE-3 study of magrolimab plus venetoclax/azacitidine vs venetoclax/azacitidine in select patients with AML has been terminated.

Belumosudil for Treatment of Chronic GVHD

February 8th 2024

The expert panel explores belumosudil's role in treating chronic GVHD after multiple systemic therapy lines. They discuss the ROCKstar trial, highlighting its overall response rates and real-world experiences.

Ibrutinib in Chronic GVHD

February 8th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the approval and real-world experiences of ibrutinib and ruxolitinib for chronic GVHD. The panel discusses the challenges and varying effectiveness observed in real-world usage, contrasting the experiences of the two drugs.

State of the Science Summit - Leukemia/Lymphoma: Chaired by Eduardo M. Sotomayor, MD

February 7th 2024

State of the Science Summit - Leukemia/Lymphoma: Chaired by Eduardo M. Sotomayor, MD

Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

February 6th 2024

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

February 6th 2024

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Patient Profile 1: A 72-Year-Old Man With MDS

February 6th 2024

Andrew Brunner, MD, presents the profile of a 72-year-old man with MDS and the panel offers their initial impressions on the case, focusing on the treatment decisions.

Current Treatment Options in Second-line MCL

February 6th 2024

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

ASH 2023 Updates on Frontline Therapies in MCL

February 6th 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia

February 6th 2024

Amy DeZern, MD, MHS, provides clinical insights on the first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Enasidenib Plus Venetoclax Yields High Response Rates Targeting IDH2 Mutations in R/R AML

February 5th 2024

The combination of the first-in-class inhibitor enasidenib plus venetoclax has generated excitement targeting IDH2 mutations in relapsed/refractory AML.

Understanding Malignancy Risks With the Use of CAR T-cell Therapies

February 5th 2024

Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.

CAR T-Cell Therapy as a Second-Line Treatment for LBCL

February 5th 2024

Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.

Dr Castillo on Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

February 2nd 2024

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.